These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2238 related articles for article (PubMed ID: 27511158)

  • 21. Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.
    Came N; Nguyen V; Westerman D; Harrison S
    Br J Haematol; 2016 Jun; 173(6):947-9. PubMed ID: 26456706
    [No Abstract]   [Full Text] [Related]  

  • 22. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
    Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease in multiple myeloma: use of magnetic resonance imaging.
    Hillengass J; Merz M; Delorme S
    Semin Hematol; 2018 Jan; 55(1):19-21. PubMed ID: 29759148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal residual disease in myeloma: are we there yet?
    Hart AJ; Jagasia MH; Kim AS; Mosse CA; Savani BN; Kassim A
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1790-9. PubMed ID: 22626785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
    Raje N; Faiman B; Harvey RD; Kurtin SE; Lonial S; Kumar SK; Cohen AD; Conde MA; Giralt SA; Recine MS; Tombler ER; Stadtmauer E; Jagannath S; Anderson KC;
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):356-69. PubMed ID: 25066040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
    Landgren O; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
    Kyle RA
    Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple Myeloma Minimal Residual Disease.
    Paiva B; García-Sanz R; San Miguel JF
    Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
    Rawstron AC; de Tute RM; Haughton J; Owen RG
    Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.
    Oliva S; D'Agostino M; Boccadoro M; Larocca A
    Front Oncol; 2020; 10():1. PubMed ID: 32076595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
    Martinez-Lopez J; Fernández-Redondo E; García-Sánz R; Montalbán MA; Martínez-Sánchez P; Pavia B; Mateos MV; Rosiñol L; Martín M; Ayala R; Martínez R; Blanchard MJ; Alegre A; Besalduch J; Bargay J; Hernandez MT; Sarasquete ME; Sanchez-Godoy P; Fernández M; Blade J; San Miguel JF; Lahuerta JJ;
    Br J Haematol; 2013 Dec; 163(5):581-9. PubMed ID: 24117042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
    Oldaker TA; Wallace PK; Barnett D
    Cytometry B Clin Cytom; 2016 Jan; 90(1):40-6. PubMed ID: 26201282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and clinical follow-up after treatment of multiple myeloma.
    Rasmussen T; Knudsen LM; Huynh TK; Johnsen HE
    Acta Haematol; 2004; 112(1-2):105-10. PubMed ID: 15179010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories].
    Jelínek T; Kořístka M; Čermáková Z; Hájek R
    Klin Onkol; 2017; 30(1):13-19. PubMed ID: 28185460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma.
    Pugh TJ
    Semin Hematol; 2018 Jan; 55(1):38-40. PubMed ID: 29759151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease.
    Thoren KL
    Semin Hematol; 2018 Jan; 55(1):41-43. PubMed ID: 29759153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
    Martinez-Lopez J; Sanchez-Vega B; Barrio S; Cuenca I; Ruiz-Heredia Y; Alonso R; Rapado I; Marin C; Cedena MT; Paiva B; Puig N; Mateos MV; Ayala R; Hernández MT; Jimenez C; Rosiñol L; Martínez R; Teruel AI; Gutiérrez N; Martin-Ramos ML; Oriol A; Bargay J; Bladé J; San-Miguel J; Garcia-Sanz R; Lahuerta JJ
    Leukemia; 2017 Jun; 31(6):1446-1449. PubMed ID: 28210002
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 112.